Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability

H. Ballentine Carter, Luigi Ferrucci, Anna Kettermann, Patricia Landis, E. James Wright, Jonathan I. Epstein, Bruce J. Trock, E. Metter

Research output: Contribution to journalArticle

233 Citations (Scopus)

Abstract

Background: Prostate-specific antigen (PSA) level is typically used as a dichotomous test for prostate cancer, resulting in overdiagnosis for a substantial number of men. The rate at which serum PSA levels change (PSA velocity) may be an important indicator of the presence of life-threatening disease. Methods: PSA velocity was determined in 980 men (856 without prostate cancer, 104 with prostate cancer who were alive or died of another cause, and 20 who died of prostate cancer) who were participants in the Baltimore Longitudinal Study of Aging for up to 39 years. The relative risks (RRs) of prostate cancer death and prostate cancer-specific survival stratified by PSA velocity were evaluated in the three groups of men by Cox regression and Kaplan-Meier analyses. Statistical tests were two-sided. Results: PSA velocity measured 10-15 years before diagnosis (when most men had PSA levels below 4.0 ng/mL) was associated with cancer-specific survival 25 years later; survival was 92% (95% confidence interval [CI] = 84% to 96%) among men with PSA velocity of 0.35 ng/mL per year or less and 54% (95% CI = 15% to 82%) among men with PSA velocity above 0.35 ng/ mL per year (P <.001). Furthermore, men with PSA velocity above 0.35 ng/mL per year had a higher relative risk of prostate cancer death than men with PSA velocity of 0.35 ng/mL per year or less (RR = 4.7, 95% CI = 1.3 to 16.5; P = .02); the rates per 100 000 person-years were 1240 for men with a PSA velocity above 0.35 ng/mL per year and 140 for men with a PSA velocity of 0.35 ng/mL per year or less. Conclusions: PSA velocity may help identify men with life-threatening prostate cancer during a period when their PSA levels are associated with the presence of curable disease.

Original languageEnglish (US)
Pages (from-to)1521-1527
Number of pages7
JournalJournal of the National Cancer Institute
Volume98
Issue number21
DOIs
StatePublished - Nov 1 2006
Externally publishedYes

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Confidence Intervals
Survival
Baltimore
Kaplan-Meier Estimate
Longitudinal Studies

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. / Carter, H. Ballentine; Ferrucci, Luigi; Kettermann, Anna; Landis, Patricia; Wright, E. James; Epstein, Jonathan I.; Trock, Bruce J.; Metter, E.

In: Journal of the National Cancer Institute, Vol. 98, No. 21, 01.11.2006, p. 1521-1527.

Research output: Contribution to journalArticle

Carter, H. Ballentine ; Ferrucci, Luigi ; Kettermann, Anna ; Landis, Patricia ; Wright, E. James ; Epstein, Jonathan I. ; Trock, Bruce J. ; Metter, E. / Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. In: Journal of the National Cancer Institute. 2006 ; Vol. 98, No. 21. pp. 1521-1527.
@article{308ee2d38f2d4d1ea362a81b946efe99,
title = "Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability",
abstract = "Background: Prostate-specific antigen (PSA) level is typically used as a dichotomous test for prostate cancer, resulting in overdiagnosis for a substantial number of men. The rate at which serum PSA levels change (PSA velocity) may be an important indicator of the presence of life-threatening disease. Methods: PSA velocity was determined in 980 men (856 without prostate cancer, 104 with prostate cancer who were alive or died of another cause, and 20 who died of prostate cancer) who were participants in the Baltimore Longitudinal Study of Aging for up to 39 years. The relative risks (RRs) of prostate cancer death and prostate cancer-specific survival stratified by PSA velocity were evaluated in the three groups of men by Cox regression and Kaplan-Meier analyses. Statistical tests were two-sided. Results: PSA velocity measured 10-15 years before diagnosis (when most men had PSA levels below 4.0 ng/mL) was associated with cancer-specific survival 25 years later; survival was 92{\%} (95{\%} confidence interval [CI] = 84{\%} to 96{\%}) among men with PSA velocity of 0.35 ng/mL per year or less and 54{\%} (95{\%} CI = 15{\%} to 82{\%}) among men with PSA velocity above 0.35 ng/ mL per year (P <.001). Furthermore, men with PSA velocity above 0.35 ng/mL per year had a higher relative risk of prostate cancer death than men with PSA velocity of 0.35 ng/mL per year or less (RR = 4.7, 95{\%} CI = 1.3 to 16.5; P = .02); the rates per 100 000 person-years were 1240 for men with a PSA velocity above 0.35 ng/mL per year and 140 for men with a PSA velocity of 0.35 ng/mL per year or less. Conclusions: PSA velocity may help identify men with life-threatening prostate cancer during a period when their PSA levels are associated with the presence of curable disease.",
author = "Carter, {H. Ballentine} and Luigi Ferrucci and Anna Kettermann and Patricia Landis and Wright, {E. James} and Epstein, {Jonathan I.} and Trock, {Bruce J.} and E. Metter",
year = "2006",
month = "11",
day = "1",
doi = "10.1093/jnci/djj410",
language = "English (US)",
volume = "98",
pages = "1521--1527",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "21",

}

TY - JOUR

T1 - Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability

AU - Carter, H. Ballentine

AU - Ferrucci, Luigi

AU - Kettermann, Anna

AU - Landis, Patricia

AU - Wright, E. James

AU - Epstein, Jonathan I.

AU - Trock, Bruce J.

AU - Metter, E.

PY - 2006/11/1

Y1 - 2006/11/1

N2 - Background: Prostate-specific antigen (PSA) level is typically used as a dichotomous test for prostate cancer, resulting in overdiagnosis for a substantial number of men. The rate at which serum PSA levels change (PSA velocity) may be an important indicator of the presence of life-threatening disease. Methods: PSA velocity was determined in 980 men (856 without prostate cancer, 104 with prostate cancer who were alive or died of another cause, and 20 who died of prostate cancer) who were participants in the Baltimore Longitudinal Study of Aging for up to 39 years. The relative risks (RRs) of prostate cancer death and prostate cancer-specific survival stratified by PSA velocity were evaluated in the three groups of men by Cox regression and Kaplan-Meier analyses. Statistical tests were two-sided. Results: PSA velocity measured 10-15 years before diagnosis (when most men had PSA levels below 4.0 ng/mL) was associated with cancer-specific survival 25 years later; survival was 92% (95% confidence interval [CI] = 84% to 96%) among men with PSA velocity of 0.35 ng/mL per year or less and 54% (95% CI = 15% to 82%) among men with PSA velocity above 0.35 ng/ mL per year (P <.001). Furthermore, men with PSA velocity above 0.35 ng/mL per year had a higher relative risk of prostate cancer death than men with PSA velocity of 0.35 ng/mL per year or less (RR = 4.7, 95% CI = 1.3 to 16.5; P = .02); the rates per 100 000 person-years were 1240 for men with a PSA velocity above 0.35 ng/mL per year and 140 for men with a PSA velocity of 0.35 ng/mL per year or less. Conclusions: PSA velocity may help identify men with life-threatening prostate cancer during a period when their PSA levels are associated with the presence of curable disease.

AB - Background: Prostate-specific antigen (PSA) level is typically used as a dichotomous test for prostate cancer, resulting in overdiagnosis for a substantial number of men. The rate at which serum PSA levels change (PSA velocity) may be an important indicator of the presence of life-threatening disease. Methods: PSA velocity was determined in 980 men (856 without prostate cancer, 104 with prostate cancer who were alive or died of another cause, and 20 who died of prostate cancer) who were participants in the Baltimore Longitudinal Study of Aging for up to 39 years. The relative risks (RRs) of prostate cancer death and prostate cancer-specific survival stratified by PSA velocity were evaluated in the three groups of men by Cox regression and Kaplan-Meier analyses. Statistical tests were two-sided. Results: PSA velocity measured 10-15 years before diagnosis (when most men had PSA levels below 4.0 ng/mL) was associated with cancer-specific survival 25 years later; survival was 92% (95% confidence interval [CI] = 84% to 96%) among men with PSA velocity of 0.35 ng/mL per year or less and 54% (95% CI = 15% to 82%) among men with PSA velocity above 0.35 ng/ mL per year (P <.001). Furthermore, men with PSA velocity above 0.35 ng/mL per year had a higher relative risk of prostate cancer death than men with PSA velocity of 0.35 ng/mL per year or less (RR = 4.7, 95% CI = 1.3 to 16.5; P = .02); the rates per 100 000 person-years were 1240 for men with a PSA velocity above 0.35 ng/mL per year and 140 for men with a PSA velocity of 0.35 ng/mL per year or less. Conclusions: PSA velocity may help identify men with life-threatening prostate cancer during a period when their PSA levels are associated with the presence of curable disease.

UR - http://www.scopus.com/inward/record.url?scp=33750582502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750582502&partnerID=8YFLogxK

U2 - 10.1093/jnci/djj410

DO - 10.1093/jnci/djj410

M3 - Article

VL - 98

SP - 1521

EP - 1527

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 21

ER -